Clinical Trials Sponsored by Sarepta Therapeutics

Total 6227 results

Sarepta Therapeutics, Inc.

Active, not recruiting

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Limb-Girdle Muscular Dystrophy, Type 2E

United States
Sarepta Therapeutics, Inc.

Active, not recruiting

Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (MOMENTUM)

Duchenne Muscular Dystrophy

United States, Belgium, Spain, United Kingdom, Netherlands, Germany, Canada, Italy
Sarepta Therapeutics, Inc.

Completed

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

Muscular Dystrophy, Duchenne

United States
Sarepta Therapeutics, Inc.

Active, not recruiting

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Limb Girdle Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Terminated

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Belgium, Canada, Spain, United Kingdom, Czechia, Germany, Israel, Bulgaria, France, Italy, Poland, Sweden
Sarepta Therapeutics, Inc.

Completed

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

Muscular Dystrophy, Duchenne

United States, Canada
Sarepta Therapeutics, Inc.

Completed

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Duchenne Muscular Dystrophy

Belgium, France, Italy, United Kingdom
Sarepta Therapeutics, Inc.

Completed

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Completed

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

Dysferlinopathy

United States
Sarepta Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD)

United States
Sarepta Therapeutics, Inc.

Completed

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

Encephalitis

United States
Sarepta Therapeutics, Inc.

Terminated

Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients

Hepatitis C
Sarepta Therapeutics, Inc.

Recruiting

An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy (ENDURE)

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Recruiting

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Limb-girdle Muscular Dystrophy

United States, Brazil, Belgium, Canada, Germany, Italy, Spain, Sweden, Turkey, United Kingdom
Sarepta Therapeutics, Inc.

Active, not recruiting

A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

Muscular Dystrophy, Duchenne

United States, Korea, Republic of, India, Slovenia, Turkey, United Kingdom, Germany, Switzerland, Spain, Czechia, France, Serbia, Taiwan, Netherlands, Mexico, Colombia, Denmark, New Zealand, Norway, Greece, Hungary, Ireland, Italy, Jo... and more
Sarepta Therapeutics, Inc.

Terminated

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

Muscular Dystrophy, Duchenne

United States, Canada
Sarepta Therapeutics, Inc.

Completed

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD)

United States
Sarepta Therapeutics, Inc.

Terminated

Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)

Cardiovascular Disease | Coronary Artery Bypass

Ukraine
Sarepta Therapeutics, Inc.

Terminated

An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease

West Nile Fever
Sarepta Therapeutics, Inc.

Completed

Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020

West Nile Virus

United States
Sarepta Therapeutics, Inc.

Terminated

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

Coronary Artery Disease | Coronary Stent Restenosis
Sarepta Therapeutics, Inc.

Recruiting

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)

Limb-girdle Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Active, not recruiting

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)

Duchenne Muscular Dystrophy

United States, Korea, Republic of, Italy, United Kingdom, Canada, Poland, Spain, France, Germany, Belgium, Australia, Czechia, Serbia, Greece, Argentina, Bulgaria, Denmark, Hungary, India, Ireland, Israel, Mexico, Russian Federation, ...
Sarepta Therapeutics, Inc.

Active, not recruiting

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)

Limb Girdle Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Terminated

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

Duchenne Muscular Dystrophy

Belgium, France, Italy, United Kingdom
Sarepta Therapeutics, Inc.

Completed

Study of Eteplirsen in DMD Patients (PROMOVI)

Duchenne Muscular Dystrophy (DMD)

United States
Sarepta Therapeutics, Inc.

Completed

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne

United States
Sarepta Therapeutics, Inc.

Completed

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Terminated

Safety Study of Single Administration Intravenous Treatment for Influenza

Influenza

United States
Sarepta Therapeutics, Inc.

Completed

Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid

Neoplasms

United States
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Enrolling by invitation

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION)

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION)

Duchenne Muscular Dystrophy

United States, Japan, Spain, Italy
Sarepta Therapeutics, Inc.
Nationwide Children's Hospital

Completed

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

Limb-Girdle Muscular Dystrophy, Type 2D
Hoffmann-La Roche
Sarepta Therapeutics, Inc.

Recruiting

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) (ENVOL)

Duchenne Muscular Dystrophy

Spain
Sarepta Therapeutics, Inc.
Hansa Biopharma AB

Active, not recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Duchenne Muscular Dystrophy

Spain
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Active, not recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (EMBARK)

Duchenne Muscular Dystrophy

United States, Japan, Taiwan, Belgium, Spain, Germany, Hong Kong, Italy, United Kingdom
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Enrolling by invitation

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (ENDEAVOR)

Muscular Dystrophy, Duchenne

United States
Rare Disease Research, LLC
Sarepta Therapeutics, Inc.

Terminated

An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.
British Medical Research Council

Completed

Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients

Duchenne Muscular Dystrophy

United Kingdom
Sarepta Therapeutics, Inc.
Baim Institute for Clinical Research

Completed

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

Coronary Artery Disease | Coronary Restenosis

Germany
Sarepta Therapeutics, Inc.
United States Department of Defense

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

Marburg Hemorrhagic Fever

United States
Sarepta Therapeutics, Inc.
United States Department of Defense

Withdrawn

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

Ebola Hemorrhagic Fever

United States
Sarepta Therapeutics, Inc.
United States Department of Defense

Completed

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

Ebola Hemorrhagic Fever

United States
Kevin Flanigan
Sarepta Therapeutics, Inc.

Completed

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.
United States Department of Defense

Completed

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Marburg Hemorrhagic Fever

United States
Imperial College London
Sarepta Therapeutics, Inc.; Department of Health, United Kingdom

Completed

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United Kingdom
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada

3

Subscribe